Glaxo Defends Handling of Avandia Heart Risks


GlaxoSmithKline said this week that a Senate report criticizing its handling of heart risks with its diabetes drug Avandia “mischaracterizes and distorts” the company’s record. As reported by the Associated Press, Glaxo is unhappy with the way the company’s response to reports of heart attacks caused by Avandia have been characterized by the Food and Drug Administration and the Senate Finance Committee.

Please see full article below for more information.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Robert Kraft, Kraft & Associates | Attorney Advertising

Written by:


Kraft & Associates on:

JD Supra Readers' Choice 2016 Awards
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.